Division of Urology, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.
Anticancer Res. 2022 Jul;42(7):3427-3434. doi: 10.21873/anticanres.15829.
BACKGROUND/AIM: Prostate cancer (PC) is one of the major diseases that affects male health and ranks as the second most frequent cancer in men worldwide. Although most newly-diagnosed PCs are well-differentiated tumors with a high cure probability, there are some patients with aggressive malignancies that show potential for recurrence and metastasis. Cytotoxic T lymphocytes are a specific immune effector cell population that mediates immune responses against cancer.
In the present study, the cytotoxicity of peripheral blood mononuclear cells (PBMCs)-derived γδ T cells and cytokine-induced killer (CIK) cells in combination with chemoradiotherapy against PC cells was evaluated using Alamar blue cell viability and cell membrane permeability assays.
Advanced PC-3 cells, which were more resistant to docetaxel (Doc), also showed higher viability following pretreatment with radiation. The cell proliferation inhibition was significantly increased upon additional γδ T or CIK treatment. Furthermore, the proportion of apoptotic cells was significantly (p<0.05) increased in the Doc-γδ T cell co-treatment group as compared with the Doc or γδ T cell treated alone group.
γδ T cell therapy may provide additional benefit compared to traditional chemoradiotherapy for PC treatment.
背景/目的：前列腺癌（PC）是影响男性健康的主要疾病之一，是全球男性第二大常见癌症。虽然大多数新诊断的 PC 是分化良好的肿瘤，具有很高的治愈概率，但有些患者的恶性肿瘤具有复发和转移的潜在风险。细胞毒性 T 淋巴细胞是一种特异性免疫效应细胞群体，介导针对癌症的免疫反应。
本研究采用 Alamar blue 细胞活力和细胞膜通透性检测，评估外周血单个核细胞（PBMC）衍生的γδ T 细胞和细胞因子诱导的杀伤（CIK）细胞与放化疗联合对 PC 细胞的细胞毒性。
对多西紫杉醇（Doc）更耐药的高级 PC-3 细胞，经放射预处理后存活率也更高。γδ T 或 CIK 联合治疗可显著增加细胞增殖抑制。此外，与单独用 Doc 或 γδ T 细胞处理相比，Doc-γδ T 细胞联合治疗组的凋亡细胞比例显著增加（p<0.05）。
与传统放化疗相比，γδ T 细胞治疗可能为 PC 治疗提供额外的益处。
